- Patients
- Clinical Research
- Find a clinical trial
- XL092-304
Renal Cancer
XL092-304
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma. Study detail: This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy
Trial overview
Medical Oncology
Renal cancer
III
Number: NCT05678673
Medical Oncologist
Dr Mark McGregor
BMBS FRACP B.Pharm (Hons)
Elizabeth Vale at Calvary Central Districts Hospital (Oncology)

Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.